Agalimmune established to develop innovative immunotherapeutics for treatment of cancer Agalimmune Ltd, a biopharmaceutical company, has been intended to develop innovative immunotherapeutics for the treating cancer, with a focus on solid tumours. The new company offers been founded by an purchase group comprising Loxbridge Study LLP and Animatrix Capital LLP. Agalimmune is based both in London and California . The funding will be used to continue the translation of Agalimmune's leading immunotherapeutic technology, AlphajectTM, licensed from the University of Massachusetts Medical School , to the clinic. Alphaject is founded on over 20 years of biomedical study carried out by UMMS Professor of Medical operation and Medicine Uri Galili, PhD, who discovered the anti-gal immune response and its role in 'hyper-acute' organ rejection.The improvement in the operating expense ratio is primarily driven by operating revenue growth and continuing execution of our expenditure initiatives, including execution on our Coventry-related cost synergies. The total company expense ratio was 17.7 % and 18.4 % for the 3rd quarters of 2013 and 2012, respectively.9 % for the third quarter of 2013 weighed against 10.2 % for the third one fourth of 2012 primarily due to lower underwriting margins in our underlying Medicare business. For the third quarter of 2013, the after-tax net income margin was 4.0 % in comparison to 5.6 % for 2012. Outstanding Shares were 367.5 million and 334.5 million as of September 30, 2013 and 2012, respectively.